Evofem biosciences, inc. (EVFM)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net loss

-80,033

-125,712

-105,305

-66,667

-43,157

-10,819

-15,016

Gain on sale of discontinued operations

-

-

-

1,077

-

-

-

Net loss from continuing operations

-

-

-

-67,744

-

-

-

Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss On Issuance Of Warrants

0

47,920

0

-

-

-

-

Loss on issuance of warrants

-

-

-8,522

-26,635

-

-

-

Loss On Issuance Of Purchase Rights

674

0

-

-

-

-

-

Change in fair value of warrants

7,755

0

-

-

-

860

490

Fair Value Adjustment Of Purchase Rights

19,617

0

-

-

-

-

-

Loss on extinguishment of related-party note payable

-

-

-

-6,651

-

-

-

Abandoned initial public offering costs

-

-

-

4,705

-

-

-

Tax benefit

-

-

-

-615

-

-

-

Liabilities, Fair Value Adjustment

0

-130

-61,175

-543

-

-

-

Non-cash interest expense on notes payable and debt

-

-

-

-

220

84

27

Stock-based compensation

8,579

17,842

861

1,431

1,578

612

80

Loss on sale of assets

-

-

-

-

-6

-

-47

Depreciation

263

262

244

92

58

17

72

Loss from sale of property and equipment

-79

0

-

-

-

-

-

Noncash lease expenses

642

0

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid and other assets

952

11

-145

153

1,051

783

-1,343

Accounts payable

-2,931

3,799

7,052

105

-

-

-

Accrued expenses and other liabilities

-8,775

-795

7,319

3,321

-

-

-

Accrued compensation

746

307

775

629

-

-

-

Operating lease liabilities

761

0

-

-

-

-

-

Deferred rent, net of current portion

0

242

30

17

-

-

-

Net cash, cash equivalents and restricted cash used in operating activities

-55,097

-56,500

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

4,433

455

51

Net cash, cash equivalents and restricted cash used in operating activities

-

-

-19,242

-24,417

-37,911

-9,572

-12,904

Cash flows from investing activities:
Proceeds from sale of property and equipment

32

0

-

-

-

-

64

Maturities of short-term investments

250

250

250

-

-

-

-

Cash acquired in connection with the Merger

0

1,900

0

-

-

-

-

Restricted cash

-

-

-

-

-

-

-40

Purchases of property and equipment

164

7

6

498

226

18

21

Purchases of property and equipment

8,233

0

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

-8,115

2,143

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

-

-

244

-498

-226

-18

83

Cash flows from financing activities:
Proceeds from issuance of common stock- exercise of warrants

6,273

0

-

-

-

-

-

Proceeds from issuance of common stock, warrants and Purchase Rights in connection with Private Placement, net of financial advisory fees

75,400

20,000

-

-

-

-

-

Proceeds from issuance of common stock, net of commissions- ATM transactions

2,960

-

-

-

-

-

-

Payments on advances from related parties, including note payable

-

-

-

4,787

-

-

-

Proceeds from issuance of common stock

-

-

9,925

24,814

-

-

-

Proceeds from issuance of common stock - private placement

-

-

0

-

-

-

-

Proceeds from issuance of common stock, net of commissions- ATM transactions

0

37,542

0

-

-

-

-

Proceeds from issuance of common stock - ESPP and exercise of stock options

305

42

-

-

-

-

-

Proceeds from bank loan

-

-

-

-

-

10,000

-

Principal payments on bank loan

-

-

-

-

-

209

-

Principal payments on bank loan

-

-

-

-

-

-

448

Proceeds from issuance of common stock - exercise of stock options

-

-

0

-

96

76

-

Repayment of Note Payable

4,010

0

-

-

-

-

-

Payment of cash dividends for Series D redeemable convertible preferred stock

0

157

0

-

-

-

-

Cash paid for financing costs

1,286

1,418

-

-

-

-

-

Issuance of common stock from employee stock purchase plan

-

-

-

-

42

-

-

Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

13,568

6,533

Proceeds from IPO, net of offering costs

-

-

-

-

-

57,738

-

Cash paid for financing costs

-

-

713

1,966

-

-

-

Payments of tax withholdings related to vesting of restricted stock awards

1,566

1,592

0

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

78,076

54,417

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

14,864

60

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

-

-

9,212

18,061

138

81,173

6,085

Net cash and restricted cash used in continuing operations

-

-

-

-6,854

-

-

-

Net cash and restricted cash provided by discontinued operating activities

-

-

-

619

-

-

-

Net cash and restricted cash provided by discontinued investing activities

-

-

-

600

-

-

-

Net change in cash, cash equivalents and restricted cash

-

-

-9,786

-5,635

-37,998

71,583

-

Cash paid for interest

-

-

15

-

-

-

-

Cash paid for taxes

4

2

3

2

-

-

-

Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities

802

0

-

-

-

-

-

Financing costs included in accounts payable and accrued expenses

306

94

-

-

-

-

-

Financing costs included in accounts payable and accrued expenses

-

-

137

850

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

10

0

-

-

-

-

-

Reclassification of warrants and Purchase Rights liability to equity

6,120

-

-

-

-

-

-

Tenant improvement allowances paid by landlord

-

-

-

162

-

-

-

Conversion of related-party note payable into Series D redeemable convertible preferred stock

-

-

-

5,000

-

-

-

Forgiveness of note payable by related-party

-

-

-

5,000

-

-

-

Proceeds from issuance of common stock included in other receivable

416

0

-

5

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-6,735

Cash paid for interest

-

-

-

73

912

351

32

Warrants issued for services in connection with issuance of preferred stock

-

-

-

-

-

142

96

Warrants issued in connection with Loan and Security Agreement

-

-

-

-

-

207

-

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

3,415

-

Conversion of convertible preferred stock into common stock

-

-

-

-

-

70,913

-

Issuance of Series D liquidation preference

-

-

10,665

7,487

-

-

-

Net assets acquired in connection with the Merger

0

46

0

-

-

-

-

Issuance of Promissory Note

-

-

0

-

-

-

-

Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

0

121,315

0

-

-

-

-

Series D Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

0

68,622

0

-

-

-

-

Series D 2X Liquidation Preference Liability
Conversion of Series D redeemable convertible preferred stock into common stock

0

80,000

0

-

-

-

-

Issuance of Promissory Note

0

4,010

-

-

-

-

-